SEC Filings TLDR

SVF Endurance (Cayman) Ltd, along with related entities SoftBank Vision Fund (AIV M1) L.P. and SB Investment Advisers (UK) Ltd, reported the sale of shares in Vir Biotechnology, Inc. (VIR) pursuant to a Rule 10b5-1 trading plan. The transactions occurred on October 24, 2025, and October 27, 2025. On October 24, 2025, 4...

Marianna Mancini, Chief Operating Officer of Viking Therapeutics, Inc., reported two significant stock transactions. On October 27, 2025, she acquired 11,117 shares of common stock at $0 per share, increasing her total holdings to 388,652 shares. This acquisition was part of a performance restricted stock unit award gr...

On October 27, 2025, Rowland Charles A Jr, a director of Viking Therapeutics, Inc., engaged in multiple transactions involving the company's common stock. He acquired a total of 60,000 shares at prices ranging from $4.48 to $5.80 per share, increasing his holdings to 90,000 shares. Subsequently, he sold 60,000 shares a...

The filing reports two significant stock transactions by Brian Lian, the President & CEO of Viking Therapeutics, Inc. On October 27, 2025, Lian acquired 70,084 shares of common stock as part of a performance restricted stock unit award that vested upon the achievement of non-financial performance goals. This transactio...

The filing details the stock transactions of Greg Zante, the Chief Financial Officer of Viking Therapeutics, Inc. On October 27, 2025, Zante acquired 11,117 shares of common stock at $0 per share, increasing his total holdings to 179,777 shares. This acquisition was part of a performance restricted stock unit award gra...

The filing details the stock transactions of Andrew D'Amico, a director at Vicor Corp, on October 24, 2025. D'Amico engaged in multiple transactions involving the company's common stock and non-qualified stock options. He acquired and disposed of shares of common stock at various prices, with transactions ranging from ...

Robert Gendron, Corporate VP - Marketing at Vicor Corp, engaged in multiple stock transactions between October 24 and October 27, 2025. These transactions included both acquisitions and disposals of common stock, as well as exercises of non-qualified stock options. Notably, Gendron acquired shares at prices ranging fro...

Philip D. Davies, Vice President of Global Sales & Marketing at Vicor Corp, sold all his shares in the company on October 24, 2025. The transactions involved the sale of 786 shares at $94.1552 per share and 14,977 shares at $91.9624 per share. Following these transactions, Davies no longer holds any shares in Vicor Cor...

On October 24, 2025, Claudio Tuozzolo, Corporate Vice President of Vicor Corp, engaged in multiple transactions involving the company's common stock and non-qualified stock options. Tuozzolo acquired and disposed of shares of common stock, with transactions totaling 1061, 3931, and 516 shares at various prices. Additio...

On October 24, 2025, Scott Darling, the Chief Legal Officer of Upstart Holdings, Inc., engaged in several transactions involving the company's common stock. Darling exercised an employee stock option to acquire 1,000 shares at $13.22 per share and subsequently sold 1,000 shares at a weighted average price of $55.0124. ...

The filing reports multiple transactions involving the sale of US Energy Corp (USEG) common stock by several 10% owners. The transactions occurred between October 23, 2025, and October 27, 2025. The sellers include Joshua Lane Batchelor, Sage Road Capital, LLC, Banner Oil & Gas, LLC, Woodford Petroleum, LLC, Benjamin A...

Michael Benkowitz, President and COO of United Therapeutics Corp, reported several transactions involving the company's common stock and stock options on October 27, 2025. These transactions included the exercise of stock options and subsequent sales of the resulting shares. The transactions were conducted under a Rule...

Richard Bradshaw, EVP and Chief Banking Officer of United Community Banks, Inc., sold 1,654 shares of the company's common stock on October 27, 2025, at a price of $30.23 per share. The transaction was conducted under a 10b5-1 plan, which allows company insiders to sell shares at predetermined times to avoid accusation...

On October 27, 2025, Geoffrey Richards, the Chief Operating Officer of Vacation Ownership at Travel & Leisure Co., sold 26,838 shares of common stock at a weighted average price of $66.0557 per share. The shares were sold in multiple transactions ranging from $66.00 to $66.14. Following this transaction, Richards owns ...

On October 24, 2025, Adamson Keelan, President and CEO of Transocean Ltd., sold 40,942 registered shares of the company at a price of $4 per share. This transaction was executed under a Rule 10b5-1 trading plan adopted on March 28, 2025. Following the sale, Keelan owns 1,370,152 shares of Transocean Ltd. The sale was r...

On October 24, 2025, Brady K. Long, EVP & Chief Legal Officer of Transocean Ltd., sold 97,090 registered shares at a price of $4.00 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on March 11, 2025. Following the sale, Long owns 1,161,409 shares directly. The filing highlights the trans...

On October 27, 2025, Kevin Stein, a director of TransDigm Group INC, engaged in several transactions involving the company's common stock and stock options. Stein acquired 700 shares of common stock at $105.88 per share, increasing his total holdings to 8,858 shares. On the same day, he disposed of 700 shares at an ave...

Patrick Murphy, Co-Chief Operating Officer of TransDigm Group INC, reported several transactions involving the company's common stock and stock options on October 27, 2025. Murphy acquired 580 shares of common stock at $269.42 per share, increasing his total holdings to 1,635 shares. On the same day, he disposed of 580...

Ryan F. Robinson, CFO of Tourmaline Bio, Inc., disposed of 14,366 shares of common stock and several employee stock options as part of the company's merger with Novartis AG. The merger, completed on October 28, 2025, involved a cash tender offer of $48.00 per share. The stock options, which were canceled and terminated...

Parvinder Thiara, a director of Tourmaline Bio, Inc., disposed of 83,782 shares of common stock and 36,800 employee stock options on October 28, 2025, following the completion of a merger with Novartis AG. The shares were tendered in exchange for $48.00 per share, as per the Merger Agreement dated September 8, 2025. Th...

Susan Dana Jones, Chief Technology Officer of Tourmaline Bio, Inc., disposed of 19,782 shares of common stock and 180,993 stock options as part of the company's merger with Novartis AG. The merger, completed on October 28, 2025, involved a cash tender offer of $48.00 per share. The stock options were canceled and conve...

On October 28, 2025, Kevin Bruce Johnson, the Chief Regulatory Officer of Tourmaline Bio, Inc., disposed of a significant number of shares and stock options in the company. This action was part of a merger agreement between Tourmaline Bio, Inc., Novartis AG, and Torino Merger Sub Inc. The merger involved a cash tender ...

On October 28, 2025, Sandeep Kulkarni, CEO of Tourmaline Bio, Inc., disposed of a significant number of shares and stock options following the completion of a merger with Novartis AG. The merger, executed through a cash tender offer, resulted in the acquisition of all outstanding shares of Tourmaline Bio at $48.00 per ...

On October 28, 2025, Aaron Kantoff, a director of Tourmaline Bio, Inc., disposed of 88,281 shares of common stock and 26,800 stock options as part of a merger agreement with Novartis AG. The shares were tendered for $48.00 per share, and the stock options were canceled in exchange for cash payments based on the differe...

On October 28, 2025, Sapna Srivastava, a director of Tourmaline Bio, Inc., disposed of 518 shares of common stock and several employee stock options as part of a merger agreement with Novartis AG. The common stock was tendered for $48.00 per share, while the stock options were canceled and converted into cash based on ...